Cellectis S.A. (CLLS)

CIK 0001627281 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest FY-2025 —
FY-2024
FY-2024 —
FY-2023 —
FY-2022

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover Page
—
Statements
Statements of Consolidated Financial Position
—
Statements of Consolidated Operations
—
Statements of Consolidated Comprehensive Income (loss)
—
Statements of Consolidated Cash Flows
—
Statements of Consolidated Cash Flows (P)
—
Condensed Statements of Changes In Consolidated Shareholders' Equity
—
Statements of Changes In Consolidated Shareholders' Equity (P)
—
Notes
Accounting Principles
—
Capital
—
Commitments
—
Current Financial Assets and Cash and Cash Equivalents
—
Cybersecurity Risk Management and Strategy
—
Cybersecurity Risk Management, Strategy and Governance
—
Deferred Income and Contract Liabilities
—
Discontinued Operations
—
Earnings Per Share
—
Financial Assets and Liabilities
—
Financial Liabilities
—
Financial Liabilities and Lease Debts
—
Impairment Tests
—
Information Concerning The Group's Consolidated Operations
—
Insider Trading Policies and Procedures
—
Intangible Assets
—
Non-current Financial Assets and Other Non-current Assets
—
Off-balance Sheet Commitments
—
Other Current Liabilities
—
Property, Plant and Equipment
—
Provisions
—
Related Parties
—
Related Parties and Other Major Shareholders
—
Right-of-use Assets
—
Scope of Consolidation and Non-consolidated Entities
—
Share-based Payments
—
Subsequent Events
—
The Company
—
Trade Receivables and Other Current Assets
—